Tango Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 18, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 18, 2024

TNGX$24.30+6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

AccumulatedOther
Common Stock Outstanding · Additional · Comprehensive · Total
	Shares	Amount	Paid-inCapital	Income(Loss)	AccumulatedDeficit	Stockholders’Equity
Balance at December 31, 2021	87,598,184	88	506,760	(765)	(161,336)	344,747
Issuance of common stock from exercise of options and employee stock purchase plan	581,190	—	1,623	—	—	1,623
Stock based compensation expense	—	—	14,230	—	—	14,230
Business combination and PIPE financing, issuance costs	—	—	(8)	—	—	(8)
Other comprehensive loss	—	—	—	(2,940)	—	(2,940)
Net loss	—	—	—	—	(108,176)	(108,176)
Balance at December 31, 2022	88,179,374	$88	$522,605	$(3,705)	$(269,512)	$249,476
Issuance of common stock from exercise of options and employee stock purchase plan	826,714	—	1,941	—	—	1,941
Stock based compensation expense	—	—	19,079	—	—	19,079
Common shares issued in offering, net of issuance costs	13,196,671	14	67,708	—	—	67,722
Pre-funded warrants issued	—	—	12,054	—	—	12,054
Return of capital from a stockholder - related party	—	—	689	—	—	689
Other comprehensive income	—	—	—	3,891	—	3,891
Net loss	—	—	—	—	(101,744)	(101,744)
Balance at December 31, 2023	102,202,759	$102	$624,076	$186	$(371,256)	$253,108

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.